Sanofi (NASDAQ:SNY) is a top pick among cheap healthcare stocks for 2026, with analysts giving it a ‘Buy’ rating and a one-year median price target of $61, indicating a 23.16% upside potential. BofA recently lowered its price target on SNY to EUR 102.

Sanofi (NASDAQ:SNY) completed the acquisition of Vicebio Ltd., enhancing its vaccine design capabilities with a combination vaccine candidate for respiratory viruses. The company also gained EC approval for Dupixent (dupilumab) for chronic spontaneous urticaria, strengthening its immunology market presence.

Founded in 1994, Sanofi (NASDAQ:SNY) is a French pharmaceutical company specializing in medicines and vaccines for various conditions. While SNY shows investment potential, consider exploring undervalued AI stocks for higher upside potential. Explore more in our free report on the best short-term AI stock.

Read more at Yahoo Finance: Why Wall Street Analysts Are Closely Watching Sanofi (SNY)